Facing increasing pressure from both industry and the White House, FDA Commissioner Marty Makary said the strong bad press against him is “corporate spin” and that the agency has “followed the science.”​ ​Read More

First quarter earnings continue to arrive, with analysts demanding more from cautious Pfizer and Eli Lilly expecting more revenue; the FDA taps Katherine Szarama as Vinay Prasad’s controversial FDA tenure ends; oncology veterans miss Richard Pazdur at the agency’s first adcomm in nine months; and QurAlis and Corcept Therapeutics spark renewed hope in ALS.

A million patients with obesity are already taking Novo Nordisk’s Wegovy pill, CEO Mike Doustdar said Wednesday, despite the market entry of Lilly’s Foundayo.

Novo’s pill had sales of 2.3 billion Danish …​ ​Read More